DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 23.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,232 shares of the medical device company’s stock after buying an additional 13,867 shares during the period. Nisa Investment Advisors LLC’s holdings in DexCom were worth $5,773,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of DXCM. Jennison Associates LLC grew its position in shares of DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Westfield Capital Management Co. LP increased its stake in shares of DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares during the last quarter. Two Sigma Advisers LP raised its holdings in shares of DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after acquiring an additional 739,000 shares during the period. Intech Investment Management LLC boosted its position in shares of DexCom by 2,083.0% during the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock valued at $25,967,000 after acquiring an additional 369,587 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of DexCom by 53.5% in the third quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock valued at $66,352,000 after purchasing an additional 345,114 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.30% of the stock is owned by company insiders.

DexCom Stock Up 1.2 %

DexCom stock opened at $88.75 on Friday. The firm has a market capitalization of $34.67 billion, a P/E ratio of 53.14, a P/E/G ratio of 2.23 and a beta of 1.12. The stock’s fifty day simple moving average is $79.25 and its 200-day simple moving average is $77.51. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Analysts Set New Price Targets

Several research firms have weighed in on DXCM. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Royal Bank of Canada cut their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein upped their price target on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. JPMorgan Chase & Co. raised their price objective on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Finally, Raymond James decreased their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.29.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.